emerging markets strategy

11.21.2013

Setting Fair-Market Value Based on Salary? Try KOL Activity Instead

By Elio Evangelista, Director of Operations Having just completed a new benchmarking study on fair-market value (FMV) rates in the Middle East, Cutting Edge Information uncovered a few important trends that may also affect country-level teams in...
 

11.18.2013 Medical Affairs

Tips for Medical Affairs Teams Fighting to Eradicate Communicable Diseases

By Jennifer Harrell, Research Analyst While ideological debates and bitter feuds over healthcare reform rage on in America, developing countries suffer from the crippling effects of neglected tropical diseases. Trachoma, for example, is an eye disease...
 

9.10.2013 Market Access

Product Pricing in Emerging Markets

By Yanis Saradjian, Director of Consulting In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics...
 

3.29.2013 Clinical Development

Clinical Research in Asia: Factors to Consider

Access to treatment-naïve patients spurs companies to look beyond the borders of their own countries.  Top markets such as the United States are home to hundreds of millions of patients, but the clinical trial market has been saturated with thousands of protocols...
 

3.25.2013 Market Access

Pricing Troubles in India: Compulsory Licensing on the Subcontinent

Fresh news out of India this week is likely to add to pharmaceutical companies' concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for...
 

3.6.2013 Brand Management

Emerging Markets Present Big Opportunities in 2013

With continuing uncertainty in established markets such as the US and Europe, pharmaceutical companies are looking further abroad in pursuit of profits.  While many companies have been laying the groundwork to move into emerging markets for many years now, analysts...
 

12.17.2012 Marketing

Pharma 3.0 Pulls Companies into the Digital Future

Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0.  Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drugs.  The diversified portfolio model of Pharma 2.0 is no longer...
 

10.8.2012 Health Economics and Outcomes Research (HEOR)

HEOR Teams Should Consider Partnerships with Academia

In a recent study on HEOR teams, we found that accessing quality data for HEOR analysis is a challenge for companies worldwide. As shown in the accompanying Figure, on a scale of 1 to 10 (with 10 being the most difficult), US companies rated accessing quality data...
 

8.20.2012 Marketing

Patient Adherence: Increased Dedication Fuels Bigger Budgets

Saying that patient adherence is straightforward is like saying the only thing required to compete at the Olympics is a plane ticket. It’s simply not true. Fostering long-term patient adherence goes beyond the scope of simply getting patients to take their...
 

8.8.2012 Marketing

Understanding the Importance of Mobile Health for Pharma

Mobile health (mHealth) may be the buzzword of today, but this one will not be just another flash in the pan. Mobile health offers the life sciences industry far-reaching capabilities to connect with various stakeholders - from patients and caregivers to physicians...